Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection
Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection
复制标题
DOI：
10.1111/j.1365-2036.2004.02027.x
复制
发表时间：
2004-07-01
影响因子：
7.6
通讯作者：
Hibi, T
中科院分区：
文献类型：
--
作者：
Suzuki, H;Nomura, S;Hibi, T
近年来，鸡蛋黄被认为是一种廉价的抗体来源，并且已经研究了蛋黄免疫球蛋白Y（IgY）在口服被动免疫中的治疗有用性。虽然多种抗生素治疗根除大多数幽门螺杆菌（H。pylori）感染，10-15%的病例由于产生耐药性而治疗失败。因此，重要的是，新的，更广泛的治疗H。幽门螺杆菌感染应确定。本研究评价了对H. pylori感染鸡的卵黄抗体IgY。幽门螺杆菌尿素酶（抗HpU IgY）。17名无症状志愿者确诊为H. 13-尿素呼气试验（UBT）检测幽门螺杆菌（Hp）阳性者，口服抗Hp IgY 4周。4周后，UBT值显著降低，但无一例出现H。根除幽门一个H。一位幽门螺杆菌阳性的53岁女性胃炎患者，服用抗HpU IgY和兰索拉唑8周后，血清胃蛋白酶原（PG）I和UBT值下降，PG I/II比值升高。结论：抗HpU IgY可减轻H.幽门相关性胃炎和部分减弱胃尿素酶活性。此外，抗HpU IgY与抗酸剂组合似乎可以改善胃炎症。这些令人鼓舞的结果可能代表了一种新的方法来管理H。幽门相关性胃十二指肠疾病
Recently, chicken egg yolk was recognized as an inexpensive antibody source, and the therapeutic usefulness of egg yolk immunoglobulin Y (IgY) in oral passive immunization has been investigated. Although multiple antibiotic treatments eradicate most Helicobacter pylori (H. pylori) infections, therapy fails in 10-15% of cases due to the development of drug resistance. Consequently, it is important that new, more broadly based therapies for the treatment of H. pylori infection should be identified. The present study evaluated the effect, on H. pylori infection, of IgY prepared from egg yolk of hens immunized with H. pylori urease (anti-HpU IgY). Seventeen asymptomatic volunteers diagnosed as H. pylori-positive by the C-13-urea breath test (UBT) were orally administered anti-HpU IgY for 4 weeks. Four weeks later, UBT values were significantly decreased although no case showed H. pylori eradication. An H. pylori-positive 53-year-old female gastritis patient administered anti-HpU IgY plus lansoprazole for 8 weeks showed a decrease in serum pepsinogen (PG) I and UBT values as well as an increase in the PG I/II ratio. In conclusion, anti-HpU IgY may mitigate H. pylori-associated gastritis and partially attenuate gastric urease activity. Furthermore, anti-HpU IgY combined with antacids appears to ameliorate gastric inflammation. These encouraging results may represent a novel approach to the management of H. pylori-associated gastroduodenal disease.